A company dedicated to transforming cancer care through precision medicine, Foundation Medicine has announced a significant partnership with Manifold, the premier artificial intelligence (AI) data platform for life sciences.

This collaboration is set to enhance Foundation Medicine's cloud-based data analytics and visualization tool, FoundationInsights®, by integrating advanced AI capabilities from Manifold. The improved platform, which is immediately available to biopharmaceutical partners, is designed to provide greater flexibility and speed in answering critical questions that arise throughout the drug development process.

By leveraging Manifold's AI data platform, FoundationInsights® can now offer a faster, more intuitive method for extracting valuable information from Foundation Medicine's proprietary and de-identified multimodal dataset, which includes genomic results from over 800,000 patients. Users can now rapidly identify patient groups and explore the prevalence of genomic alterations using simple, natural language searches powered by AI to define complex genomic criteria. For technical users requiring more in-depth analysis, the platform still offers the flexibility to perform customized analyses using popular programming languages like Python and R. This move underscores Foundation Medicine's commitment to using AI and machine learning to accelerate drug discovery, providing partners with a "one-stop shop" to combine comprehensive multimodal data with advanced analytics and visualization tools. According to both companies, this synergy will enable researchers to work smarter and faster, ultimately accelerating the discovery of innovative personalized therapies, with a version of the enhanced FoundationInsights® also planned for healthcare providers and health systems in 2026.